| COMPANY |
Kiromic BioPharma, Inc. |
| COURT |
United States District Court for the Southern District of New York |
| CASE NUMBER |
22-cv-06690 |
| JUDGE |
The Honorable Jennifer H. Rearden |
| CLASS PERIOD |
June 25, 2021 and August 5, 2022 |
| SECURITY TYPE |
Common Stock |
Case Background:
A class action lawsuit has been filed on behalf of those who purchased or acquired Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) common stock between June 25, 2021 and August 5, 2022, inclusive (the "Class Period").
In late June 2021, Kiromic conducted an initial public offering (IPO) which closed on July 2, 2021. At the time of the IPO, Kiromic presented itself as a target discovery and gene-editing company which utilized artificial intelligence to create immunotherapy products. Although Kiromic had no immunotherapy products on the market at the time, it had applications to begin human clinical trials for two new drug candidates, known as Investigational New Drug (IND) applications, pending with the FDA. The company’s public filings in connection with the IPO stated that Kiromic could commence clinical trials within thirty days of those IND applications unless the FDA imposed a clinical hold.
Current Status of Case:
On September 29, 2023, Lead Plaintiffs filed a Motion for Preliminary Approval of Class Action Settlement. This motion is fully briefed and pending before the Court. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.